Figure 1
Schematic representation of CASA-AF study design. AAD, anti-arrhythmic drugs; AF, atrial fibrillation; AFEQT, AF Effect on QualiTy-of-life questionnaire; AT, atrial tachycardia; CMRI, cardiac magnetic resonance imaging; ECG, electrocardiogram; EHRA, European Heart Rhythm Association score for AF; EQ-5D-5L, quality of life questionnaire; HEQ, health economic questionnaire; IL, implantable loop recorder; TTE, trans thoracic echocardiogram.

Schematic representation of CASA-AF study design. AAD, anti-arrhythmic drugs; AF, atrial fibrillation; AFEQT, AF Effect on QualiTy-of-life questionnaire; AT, atrial tachycardia; CMRI, cardiac magnetic resonance imaging; ECG, electrocardiogram; EHRA, European Heart Rhythm Association score for AF; EQ-5D-5L, quality of life questionnaire; HEQ, health economic questionnaire; IL, implantable loop recorder; TTE, trans thoracic echocardiogram.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close